Ncardia(formally Axiogenesis AG and Pluriomics) is a leading provider of commercial-grade in vitro differentiated cells (e.g. cardiac, neural) derived from human induced pluripotent stem cells (iPSC), along with validated assays. Assays for each cell type have been developed for advanced drug discovery, safety / toxicology, and disease /tissue modeling. Our innovative and proprietary cell types and assays accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency.
Ncardia's innovative and proprietary cell types and assays accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency.
In vitro differentiated human cardiomyocytes are an essential tool not only for general cardiovascular research but also to address key unmet needs in drug development and pre-clinical research markets.
The importance of advanced cell-based assays in preclinical drug discovery and development has risen significantly in recent years, with a major focus on cell metabolism and the use of models that better represent physiological and pathological conditions in cancer, cardiovascular and other diseases.